首页  >  学科前沿 {{articleInfo.dynamicName}}  > 国际TOP10医学期刊药物治疗信息 (2023年12月)

国际TOP10医学期刊药物治疗信息 (2023年12月)

{{releTime.slice(0,10)}}     来源:药物治疗网     编辑:艾玉娇     阅读量:20998

一、临床肿瘤杂志 (2023年第73卷第6期)

November/December 2023 - Volume 73 - Issue 6 (2023年11/12月第73卷第6期)
https://acsjournals.onlinelibrary.wiley.com/toc/15424863/2023/73/6

二、柳叶刀 (2023年第402卷第10417-104120期)

(一)02 December 2023 - Volume 402 - Issue 10417 (2023年12月2日第402卷第10417期)
https://www.thelancet.com/journals/lancet/issue/vol402no10417/PIIS0140-6736(23)X0049-X

COMMENT(评论)
1.持续与停止催产素刺激对活动分娩和新生儿发病率的影响
(Continued versus discontinued oxytocin stimulation in active labour and neonatal morbidity)
作者:Julie Glavind* (Department of Clinical Medicine, Obstetrics and Gynecology, Aarhus University Hospital, Denmark)

CORRESPONDENCE(通信)
2.英国的碘甲状腺原氨酸处方:成本与需求
(Liothyronine prescribing in England: costs versus need)
作者:Adrian Heald* (The School of Medicine and Manchester Academic Health Sciences Centre, University of Manchester, UK)

ARTICLES(文章)
3.sparsentan与厄贝沙坦在IgA肾病患者中的疗效和安全性比较(PROTECT):一项随机、主动对照、3期试验的2年结果
(Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial)
作者:Brad H Rovin* (Division of Nephrology, Ohio State University Wexner Medical Center, USA)
4.在主动分娩中停用催产素对新生儿发病率的影响:一项开放标签、多中心、随机试验
(Impact of discontinuing oxytocin in active labour on neonatal morbidity: an open-label, multicentre, randomised trial)
作者:Aude Girault* (Department of Obstetrics and Gynecology, Port-Royal Maternity Hospital, France)
5.在恶性疟原虫和间日疟原虫共同流行地区,伯氨喹对恶性疟原虫患者的根治作用(PRIMA):一项多中心、开放标签、优效性随机对照试验
(Primaquine radical cure in patients with Plasmodium falciparum malaria in areas co-endemic for P falciparum and Plasmodium vivax (PRIMA): a multicentre, open-label, superiority randomised controlled trial)
作者:Kamala Thriemer* (Global and Tropical Health Division, Menzies School of Health Research and Charles Darwin University, Australia)

(二)09 December 2023 - Volume 402 - Issue 10418 (2023年12月09日第402卷第10418期)
https://www.thelancet.com/journals/lancet/issue/vol402no10418/PIIS0140-6736(23)X0050-6

COMMENT(评论)
1.联合化疗、曲妥珠单抗和免疫检查点抑制剂治疗HER2阳性胃食管癌
(Combining chemotherapy, trastuzumab, and immune-checkpoint inhibitors in HER2-positive gastro-oesophageal cancer)
作者:Elizabeth C Smyth* (Oxford National Institute for Health and Care Research Biomedical Research Centre, Churchill Hospital, UK)

ARTICLES(文章)
2.帕博利珠单抗联合曲妥珠单抗和化疗治疗HER2阳性胃癌或胃食管交界处腺癌:3期KEYNOTE-811随机安慰剂对照试验的中期分析
(Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial)
作者:Yelena Y Janjigian* (Memorial Sloan Kettering Cancer Center, USA)

(三)16 December 2023 - Volume 402 - Issue 10419 (2023年12月16日第402卷第10419期)
https://www.thelancet.com/journals/lancet/issue/vol402no10419/PIIS0140-6736(23)X0051-8

COMMENT(评论)
1.帕博利珠单抗联合化疗治疗胸膜间皮瘤
(Pembrolizumab plus chemotherapy for pleural mesothelioma)
作者:Y C Gary Lee* (Pleural Medicine Unit, Institute for Respiratory Health, AustraliaSchool of Medicine, University of Western Australia, AustraliaDepartment of Respiratory Medicine, Sir Charles Gairdner Hospital, Australia)

ARTICLES(文章)
2.在加拿大、意大利和法国,未经治疗的晚期胸膜间皮瘤中使用帕博利珠单抗联合化疗与单纯化疗治疗的比较:一项3期、开放标签、随机对照试验
(Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial)
作者:Quincy Chu1, Francesco Perrone2, Laurent Greillier3, Wei Tu4, Lesley Seymour4* (1. Cross Cancer Institute, Canada; 2. Istituto Nazionale Tumori Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Fondazione G Pascale, Italy; 3. Aix Marseille Univ, France; 4. Canadian Cancer Trials Group, Queen's University, Canada)
3.Ubrogepant治疗前驱期偏头痛发作:在美国进行的一项 3 期、多中心、随机、双盲、安慰剂对照、交叉试验
(Ubrogepant for the treatment of migraine attacks during the prodrome: a phase 3, multicentre, randomised, double-blind, placebo-controlled, crossover trial in the USA)
作者:David W Dodick* (Atria Academy of Science and Medicine, USA)

(四)23 December 2023 - Volume 402 - Issue 10420 (2023年12月23日第402卷第10420期)
https://www.thelancet.com/journals/lancet/issue/vol402no10420/PIIS0140-6736(23)X0052-X

三、新英格兰医学杂志 (2023年12月第389卷第23-26期)

(一)7 December 2023 - Volume 389 - No 23 (2023年12月7日第389卷第23期)
https://www.nejm.org/toc/nejm/389/23

ORIGINAL ARTICLES(原创文章)
1.索托拉西布联合帕尼单抗治疗KRAS G12C突变的难治性结直肠癌
(Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C)
作者:Marwan G. Fakih* (Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, USA)
2.巴瑞替尼与新发1型糖尿病患者的β细胞功能
(Baricitinib and β-Cell Function in Patients with New-Onset Type 1 Diabetes)
作者:Michaela Waibel, Thomas W.H. Kay* (St. Vincent’s Institute of Medical Research, Australia)
3.泰普利单抗与新诊断的1型糖尿病的β细胞功能
(Teplizumab and β-Cell Function in Newly Diagnosed Type 1 Diabetes)
作者:Eleanor L. Ramos, Kevan C. Herold* (Provention Bio, a Sanofi company, USA; Departments of Immunobiology and Internal Medicine, Yale University, USA)
4.索米妥昔单抗治疗FRα阳性铂类耐药卵巢癌
(Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer)
作者:Kathleen N. Moore* (the Stephenson Cancer Center Section of Gynecologic Oncology, University of Oklahoma Health Sciences Center, France)

EDITORIAL(社论)
5.结直肠癌靶向KRAS的联合治疗和适当剂量
(Combination Therapy and Appropriate Dosing to Target KRAS in Colorectal Cancer)
作者:Rona Yaeger (Department of Medicine, Memorial Sloan Kettering Cancer Center, USA)

CORRESPONDENCE(通信)
6.Tominersen治疗成人显性亨廷顿病
(Tominersen in Adults with Manifest Huntington’s Disease)
作者:Sarah J. Tabrizi* (University College London Queen Square Institute of Neurology, UK)
7.Pegozafermin治疗NASH的随机试验
(Randomized Trial of Pegozafermin in NASH)

(二)14 December 2023 - Volume 389 - No 24 (2023年12月14日第389卷第24期)
https://www.nejm.org/toc/nejm/389/24

ORIGINAL ARTICLES(原创文章)
1.司美格鲁肽和非糖尿病肥胖患者的心血管结局
(Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes)
作者:A. Michael Lincoff* (Department of Cardiovascular Medicine, Cleveland Clinic, UK)
2.65岁以下成人接种重组或标准剂量流感疫苗
(Recombinant or Standard-Dose Influenza Vaccine in Adults under 65 Years of Age)
作者:Amber Hsiao, Nicola P. Klein* (Kaiser Permanente Vaccine Study Center, USA)
3.转移性葡萄膜黑色素瘤患者接受Tebentafusp治疗后的3年总生存率
(Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma)
作者:Jessica C. Hassel, Paul Nathan* (University Hospital Heidelberg, Germany; Mount Vernon Cancer Centre, UK)

EDITORIAL(社论)
4.安全有效的RSV免疫接种开发取得新进展
(Continued Progress in the Development of Safe and Effective RSV Immunizations)
作者:Amanda C. Cohn (National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, USA)

CORRESPONDENCE(通信)
5.接种疫苗后抗Mpox病毒的抗体滴度
(Antibody Titers against Mpox Virus after Vaccination)
6.心房高发生率发作患者的依度沙班抗凝治疗
(Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes)
7.GLP-1受体激动剂Orforglipron治疗成人肥胖症
(GLP-1 Receptor Agonist Orforglipron for Adults with Obesity)

(三)21 December 2023 - Volume 389 - No 25 (2023年12月21日第389卷第25期)
https://www.nejm.org/toc/nejm/389/25

ORIGINAL ARTICLES(原创文章)
1.多西环素预防女性性传播感染
(Doxycycline Prophylaxis to Prevent Sexually Transmitted Infections in Women)
作者:Jenell Stewart* ( Division of Infectious Diseases, Hennepin Healthcare Research Institute, USA)
2.辛伐他汀治疗 Covid-19 危重患者
(Simvastatin in Critically Ill Patients with Covid-19)
作者:The REMAP-CAP Investigators

EDITORIAL(社论)
3.多西环素用于女性性传播感染暴露后的预防-获益不确定,但需求迫切
(Doxycycline Postexposure Prophylaxis for STIs in Women — Uncertain Benefit, Urgent Need)
作者:Jeanne Marrazzo (National Institutes of Health, USA)

CORRESPONDENCE(通信)
4.索马鲁肽与射血分数保留的心力衰竭和肥胖
(Semaglutide and Heart Failure with Preserved Ejection Fraction and Obesity)

CORRECTION(校正)
5.子宫内暴露于帕博利珠单抗后出现的严重免疫相关性肠炎
(Severe Immune-Related Enteritis after In Utero Exposure to Pembrolizumab)

(四)28 December 2023 - Volume 389 - No 26 (2023年12月28日第389卷第26期)
https://www.nejm.org/toc/nejm/389/26

ORIGINAL ARTICLES(原创文章)
1.缺血性卒中后72小时内的双联抗血小板治疗
(Dual Antiplatelet Treatment up to 72 Hours after Ischemic Stroke)
作者:Ying Gao, Weiqi Chen, Yilong Wang* (Department of Neurology, Beijing Tiantan Hospital, China)
2.尼塞韦单抗用于预防婴儿因RSV住院
(Nirsevimab for Prevention of Hospitalizations Due to RSV in Infants)
作者:Simon B. Drysdale1, Katrina Cathie2, Florence Flamein3, Markus Knuf4, Andrea M. Collins5, Pierre Tissières6, Simon Royal7, Saul N. Faust2* (1. Centre for Neonatal and Paediatric Infections, St. George’s, University of London, and the Department of Paediatrics, St. George’s University Hospitals National Health Service (NHS) Foundation Trust, UK; 2. National Institute for Health Research Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, and the Faculty of Medicine and Institute for Life Sciences, University of Southampton, UK; 3. Université de Lille, INSERM, Centre Hospitalier Universitaire (CHU) de Lille, France; 4. Children’s Hospital, Worms, Germany; 5. Liverpool University Hospitals Foundation, NHS Trust, UK; 6. Pediatric Intensive Care, Neonatal Medicine and Pediatric Emergency Department, Assistance Publique–Hôpitaux de Paris, Paris–Saclay University, Bicêtre Hospital, France; 7. University of Nottingham Health Service, University of Nottingham, UK)
3.司帕生坦与厄贝沙坦治疗局灶节段性肾小球硬化的比较
(Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis)
作者:Michelle N. Rheault, Howard Trachtman* (Division of Pediatric Nephrology, University of Minnesota Medical School, Australia;  Division of Nephrology, Department of Pediatrics, Taubman Health Sciences Center, University of Michigan, USA)

EDITORIAL(社论)
4.延长TIA或卒中的双联抗血小板治疗
(Extending Dual Antiplatelet Therapy for TIA or Stroke)
作者:Anthony S. Kim (UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, USA)
5.呼吸道合胞病毒预防——突破与挑战
(RSV Prevention — Breakthroughs and Challenges)
作者:Natasha B. Halasa (Vanderbilt University Medical Center, USA)
6.司帕生坦—治疗FSGS的另一选择?
(Sparsentan — Another Arrow in the Quiver for Treatment of FSGS?)
作者:Julie R. Ingelfinger

CORRESPONDENCE(通信)
7.头孢吡咯治疗金黄色葡萄球菌菌血症
(Ceftobiprole for Staphylococcus aureus Bacteremia)

四、美国医学会杂志 (2023年12月第330卷第21-26期)

(一)5 December 2023 -Volume 330 - No.21 (2023年12月5日第330卷第21期)
https://jamanetwork.com/journals/jama/issue/330/21

Original Investigation(原始调查)
1.信迪利单抗联合化疗治疗不可切除的胃癌或胃食管交界处癌:ORIENT-16 随机临床试验
(Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer: The ORIENT-16 Randomized Clinical Trial)
作者:Jianming Xu (The Fifth Medical Center, Chinese PLA General Hospital, China)
2.Lepodisiran,一种靶向脂蛋白(a)的长时程短干扰RNA:一项随机剂量递增临床试验
(Lepodisiran, an Extended-Duration Short Interfering RNA Targeting Lipoprotein(a): A Randomized Dose-Ascending Clinical Trial)
作者:Steven E. Nissen (Cleveland Clinic Center for Clinical Research, USA)

Medical News & Perspectives(医学新闻与亮点)
3.IDWeek 2023亮点——新疫苗、人工智能和抗菌素耐药性
(Highlights From IDWeek 2023—New Vaccines, Artificial Intelligence, and Antimicrobial Resistance)
作者:Preeti Malani
4.每周基础胰岛素对1型糖尿病可能同样有效
(Weekly Basal Insulin May Be Equally Effective for Type 1 Diabetes)
作者:Emily Harris

(二)12 December 2023 -Volume 330 - No.22 (2023年12月12日第330卷第22期)
https://jamanetwork.com/journals/jama/issue/330/22

Original Investigation(原始调查)
1.阿司匹林和使用左心室辅助装置治疗晚期心力衰竭的血液相容性事件:ARIES-HM3 随机临床试验
(Aspirin and Hemocompatibility Events With a Left Ventricular Assist Device in Advanced Heart Failure: The ARIES-HM3 Randomized Clinical Trial)
作者:Mandeep R. Mehra (Brigham and Women’s Hospital and Harvard Medical School, USA)
2.二甲双胍联合胰岛素治疗妊娠早期的原有糖尿病或妊娠期糖尿病:MOMPOD 随机临床试验
(Metformin Plus Insulin for Preexisting Diabetes or Gestational Diabetes in Early Pregnancy: The MOMPOD Randomized Clinical Trial)
作者:Kim A. Boggess (University of North Carolina at Chapel Hill School of Medicine, USA)

Editorial(社论)
3.二甲双胍治疗妊娠期糖尿病:我们是否更接近于定义它的作用?
(Metformin for Diabetes in Pregnancy: Are We Closer to Defining Its Role?)
作者:Denice S. Feig (Medicine, University of Toronto, Canada)

Medical News & Perspectives(医学新闻与观点)
4.随着司美格鲁肽人气飙升,罕见但严重的不良反应正在出现
(As Semaglutide’s Popularity Soars, Rare but Serious Adverse Effects Are Emerging)
作者:Kate Ruder
5.FDA批准Tirzepatide以 Zepbound 的名义上市,用于慢性体重管理
(FDA Green-Lights Tirzepatide, Marketed as Zepbound, for Chronic Weight Management)
作者:Jennifer Abbasi

Medical News in Brief(医学新闻简讯)
6.风险-获益比可能倾向于较低的口服抗凝剂量
(Risk-Benefit Ratio Might Favor Lower Oral Anticoagulant Doses)
作者:Emily Harris
7.多管齐下减少了尿路感染的抗生素使用
(Multipronged Approach Reduced Antibiotic Use for UTIs)
作者:Emily Harris

(三)19 December 2023 -Volume 330 - No.23 (2023年12月19日第330卷第23期)
https://jamanetwork.com/journals/jama/issue/330/23

Medical News & Perspectives(医学新闻与观点)
1.AHA 2023 亮点——新的风险计算器、索马鲁肽和心血管疾病等
(Highlights From AHA 2023—New Risk Calculator, Semaglutide and CVD, and More)
作者:Jennifer Abbasi

Medical News in Brief(医学新闻简讯)
2.FDA批准第一批基孔肯雅热疫苗
(FDA Approves First Chikungunya Vaccine)
作者:Emily Harris
3.司美格鲁肽改善了非糖尿病患者的心血管健康
(Semaglutide Improved Cardiovascular Health in People Without Diabetes)
作者:Emily Harris

Comment & Response(评论与回应)
4.Donanemab在早期有症状阿尔茨海默病中的应用
(Use of Donanemab in Early Symptomatic Alzheimer Disease)
作者:Nunzio Pomara (Nathan S. Kline Institute for Psychiatric Research, NYU Grossman School of Medicine, USA)
5.Donanemab在早期有症状阿尔茨海默病中的应用——回复
(Use of Donanemab in Early Symptomatic Alzheimer Disease—Reply)
作者:Cynthia D. Evans (Eli Lilly and Company, USA)
6.产前静脉注射镁与后代的神经发育结局
(Prenatal Intravenous Magnesium and Neurodevelopmental Outcomes in Offspring)
作者:Stéphane Marret(Department of Neonatology and Intensive Care–Neuropediatrics, Rouen University Hospital–Charles-Nicolle, France)
7.产前静脉注射镁与后代的神经发育结局——回复
(Prenatal Intravenous Magnesium and Neurodevelopmental Outcomes in Offspring—Reply)
作者:Caroline A. Crowther (Liggins Institute, University of Auckland, New Zealand)

(四)26 December 2023 -Volume 330 - No.24 (2023年12月26日第330卷第24期)
https://jamanetwork.com/journals/jama/issue/330/24

Original Investigation(原始调查)
1.高剂量氟伏沙明和COVID-19 门诊患者持续康复时间的关系:ACTIV-6 随机临床试验
(Higher-Dose Fluvoxamine and Time to Sustained Recovery in Outpatients With COVID-19: The ACTIV-6 Randomized Clinical Trial)
作者:Thomas G. Stewart (School of Data Science, University of Virginia, USA)

Medical News & Perspectives(医学新闻与观点)
2.决定何时停用药物比继续用药更好
(Deciding When It’s Better to Deprescribe Medicines Than to Continue Them)
作者:Rita Rubin
3.长期多动症药物和心血管疾病风险
(Long-Term ADHD Medications and Cardiovascular Disease Risk)
作者:Emily Harris
4.首个衣原体和淋病居家检测获得FDA批准
(First At-Home Test for Chlamydia and Gonorrhea Receives FDA Approval)
作者:Emily Harris

五、自然:药物发现综述 (2023年12月第22卷)

December 2023 - Volume 22 - Issue 12 (2023年12月第22卷第12期)
https://www.nature.com/nrd/volumes/22/issues/12

COMMENT(社论)
1.IRDiRC药物再利用指南:更好地利用现有药物治疗罕见疾病
(IRDiRC Drug Repurposing Guidebook: making better use of existing drugs to tackle rare diseases)
作者:Anneliene Hechtelt Jonker, Anna Maria Gerdina Pasmooij* (IRDiRC, France)

NEWS(新闻)
2.生物技术公司利用cGAS治疗自身免疫性疾病
(Biotechs step on cGAS for autoimmune diseases)
作者:Asher Mullard

NEWS IN BRIEF(简讯)
3.胶基KRAS抑制剂在癌症试验标志中首次亮相
(Glue-based KRAS inhibitors make their debut cancer trial mark)
作者:Asher Mullard
4.FDA批准C5阻断大环肽用于治疗自身免疫性疾病
(FDA approves C5-blocking macrocyclic peptide for autoimmune disease)
作者:Asher Mullard

Article(文章)
5.公司在大分子药物发现方面的人工智能前景
(The company landscape for artificial intelligence in large-molecule drug discovery)
作者:Navraj S. Nagra* (McKinsey & Company, UK)

RESEARCH HIGHLIGHT(研究亮点)
6.磷酸酶抑制剂驱动抗癌免疫反应
(Phosphatase inhibitor drives anticancer immune responses)
作者:Alex Eccleston
7.一种通过血脑屏障给药的新型穿梭器
(A new shuttle for drug delivery across the blood–brain barrier)
作者:Katie Kingwell
8.章鱼吸盘模拟物促进药物吸收
(Octopus sucker mimic boosts drug absorption)
作者:Sarah Crunkhorn
9.了解氯胺酮的长效作用
(Understanding long-lasting ketamine effects)
作者:Sarah Crunkhorn

Review Article(评论文章)
10.发现抗生素治疗革兰阴性菌感染的未实现靶点
(Unrealized targets in the discovery of antibiotics for Gram-negative bacterial infections)
作者:Ursula Theuretzbacher, Laura J. V. Piddock* (Center for Anti-Infective Agents, Austria;Global Antibiotic Research and Development Partnership (GARDP), Switzerland)
11.血液系统恶性肿瘤中嵌合抗原受体-T细胞的耐药机制
(Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies)
作者:Marco Ruella1, Felix Korell2, Patrizia Porazzi1, Marcela V. Maus2* (1. Division of Hematology and Oncology and Center for Cellular Immunotherapies, University of Pennsylvania, USA; 2. Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, USA)

六、自然:免疫学综述 (2023年12月第23卷第12期)

December 2023 - Volume 23 - Issue 12 (2023年12月第23卷第12期)
https://www.nature.com/nri/volumes/23/issues/12

七、柳叶刀:呼吸医学 (2023年第11卷第12期)

December 2023 - Volume 11 - Number 12 (2023年第11卷第12期)
https://www.thelancet.com/journals/lanres/issue/vol11no12/PIIS2213-2600(23)X0012-5

COMMENT(社论)
1.重症COVID-19的治疗:JAK和补体抑制剂的作用?
(Treatment of severe COVID-19: a role for JAK and complement inhibitors?)
作者:Antoine Goury, Bruno Mourvillier* (CHU Reims, Médecine Intensive et Réanimation Polyvalente, France)
2.鼻腔递送的SARS-CoV-2疫苗:未来的前景与挑战
(Nasally delivered SARS-CoV-2 vaccines: future promise and challenges)
作者:Robert H Shaw* (Oxford Vaccine Group, University of Oxford, UK)

ARTICLES(文章)
3.静脉注射依库珠单抗治疗机械通气的重症COVID-19住院患者:一项3期、多中心、开放标签、随机对照试验
(Intravenous ravulizumab in mechanically ventilated patients hospitalised with severe COVID-19: a phase 3, multicentre, open-label, randomised controlled trial)
作者:Djillali Annane1, Sean J Pittock2, Austin Kulasekararaj3* (1. Department of Intensive Care, Raymond Poincaré Hospital (Assistance Publique–Hôpitaux de Paris), France; 2. Department of Neurology, Center for MS and Autoimmune Neurology, Mayo Clinic, USA; 3. Department of Haematological Medicine, King's College Hospital, UK)
4.巴瑞克替尼或依库珠单抗在成年重症COVID-19患者中的疗效和安全性 (TACTIC-R):一项随机、平行组、开放标签的4期试验
(Efficacy and safety of baricitinib or ravulizumab in adult patients with severe COVID-19 (TACTIC-R): a randomised, parallel-arm, open-label, phase 4 trial)
作者:Frances C Hall* (Department of Medicine, Cambridge University Hospitals NHS Foundation Trust, UK)
5.SARS-CoV-2鼻内喷雾疫苗dNS1-RBD的安全性和有效性:一项多中心、随机、双盲、安慰剂对照、3期试验
(Safety and efficacy of the intranasal spray SARS-CoV-2 vaccine dNS1-RBD: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial)
作者:Fengcai Zhu1, Shoujie Huang2, Xiaohui Liu2, Qi Chen2, Chunlan Zhuang2, Hui Zhao3, Ting Wu2*, Jun Zhang2*, Ningshao Xia2* (1. Jiangsu Provincial Center for Disease Control and Prevention, Public Health Research Institute of Jiangsu Province, China; 2. State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, Department of Laboratory Medicine, School of Public Health, Xiamen University, China; 3. National Institute for Food and Drug Control, China)
6.在美国一个大型医疗系统中,BNT162b2 BA.4/5双价mRNA疫苗对一系列COVID-19结局的预防效果:一项检测阴性病例对照研究
(Effectiveness of BNT162b2 BA.4/5 bivalent mRNA vaccine against a range of COVID-19 outcomes in a large health system in the USA: a test-negative case–control study)
作者:Sara Y Tartof* (Department of Research & Evaluation, Kaiser Permanente Southern California, USA)

八、英国医学期刊 (2023年12月第383卷第8409-8411期)

(一)02 December 2023 - Volume 383 - Issue 8409 (2023年12月2日第383卷第8409期)
https://www.bmj.com/content/383/8409

News(新闻)
1.囊性纤维化:“特效药”Kaftrio的下一步规划是什么?
(Cystic fibrosis: What next for the “wonder drug” Kaftrio?)
作者:Jacqui Wise

(二)09 December 2023 - Volume 383 - Issue 8410 (2023年12月09日第383卷第8410期)
https://www.bmj.com/content/383/8410

News(新闻)
1.MHRA表示,丙戊酸钠的处方规定将从明年1月开始收紧
(Valproate prescribing rules will tighten from January, says MHRA)
作者:Elisabeth Mahase

Practice(实践)
2.世界卫生组织关于covid-19药物使用的现行指南
(A living WHO guideline on drugs for covid-19)
作者:Arnav Agarwal1, Bram Rochwerg1*, Beverley Hunt2*, Miriam Stegemann3*, Gordon Guyatt 1*(1. Department of Health Research Methods, Evidence and Impact, McMaster University, Canada; 2. King’s College London, St Thomas’ Hospital, UK; 3. National Institute of Tuberculosis and Respiratory Diseases, India)

(三)23 December 2023 - Volume 383 - Issue 8411 (2023年12月23日第383卷第8411期)
https://www.bmj.com/content/383/8411

Research(研究)
1.一种针对勃起功能障碍的药物,有助于提高生育能力、性活动和健康:孟德尔随机研究
(A drug target for erectile dysfunction to help improve fertility, sexual activity, and wellbeing: mendelian randomisation study)
作者:Benjamin Woolf* (School of Psychological Science, University of Bristol, UK)

九、自然:医学 (2023年12月第29卷第12期)

December 2023 - Volume 29 - Issue 12 (2023年12月第29卷第12期)
https://www.nature.com/nm/volumes/29/issues/12

NEWS(新闻)
1.靶向血管紧张素原的RNA干扰治疗可降低血压
(RNA interference treatment targeting angiotensinogen lowers blood pressure)
作者:Thiago Carvalho*

Year in Review(年度回顾)
2.一种治疗心力衰竭的肥胖药物
(An obesity drug for heart failure)
作者:Karen O’Leary

Comment(社论)
3.GLP-1受体激动剂在治疗酒精和物质使用障碍方面的作用有待证实
(GLP-1 receptor agonists are promising but unproven treatments for alcohol and substance use disorders)
作者:Lorenzo Leggio* (Clinical Psychoneuroendocrinology and Neuropsychopharmacology Section, Translational Addiction Medicine Branch, National Institute on Drug Abuse Intramural Research Program and National Institute on Alcohol Abuse and Alcoholism Division of Intramural Clinical and Biological Research, National Institutes of Health, USA)

Article(文章)
4.纳武利尤单抗联合伊匹木单抗治疗晚期唾液腺癌:一项2期试验
(Nivolumab plus ipilimumab in advanced salivary gland cancer: a phase 2 trial)
作者:Joris L. Vos1, Bharat Burman2, Alan L. Ho2*, Luc G. T. Morris1* (1. Head and Neck Service and Immunogenomic Oncology Platform, Department of Surgery, Memorial Sloan Kettering Cancer Center, USA; 2. Department of Medicine, Memorial Sloan Kettering Cancer Center, USA)
5.细胞注射与皮质类固醇注射在治疗骨关节炎膝关节疼痛方面的比较:一项随机3期试验
(Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial)
作者:Ken Mautner*, Michael Gottschalk, Hicham Drissi* (Department of Orthopaedics, Emory University, USA)
6.IRAK4降解剂在化脓性汗腺炎和特应性皮炎中的应用:一项1期试验
(IRAK4 degrader in hidradenitis suppurativa and atopic dermatitis: a phase 1 trial)
作者:Lindsay Ackerman, Jared A. Gollob* (Medical Dermatology Specialists, USA; Kymera Therapeutics, Inc., USA)

Author Correction(作者更正)
7.作者更正:达格列净治疗心力衰竭伴射血分数改善:一项对DELIVER试验的预设分析
(Author Correction: Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial)
作者:Orly Vardeny*, Scott D. Solomon* (Minneapolis VA Center for Care Delivery and Outcomes Research, University of Minnesota, USA; Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School, USA)

Publisher Correction(出版商更正)
8.出版商更正:ABACUS试验中阿替利珠单抗治疗可手术尿路上皮癌的临床疗效和生物标志物分析
(Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial)
作者:Thomas Powles* (Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, UK)

十、世界精神病学 (2023年第22卷第3期)

(一)2023 - Volume 22 - Issue 3 (2023年第22卷第3期)
https://onlinelibrary.wiley.com/toc/20515545/2023/22/3

网友评论